12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cabozantinib regulatory update

In December, Exelixis began submission of a rolling NDA to FDA for cabozantinib for medullary thyroid cancer (MTC). The company plans to complete the submission this half. The...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >